CNBX Pharmaceuticals Inc.
Close on Oct 19, 2026
- Market cap
- $197.79K
- P/E (TTM)
- –
- Dividend yield
- –
About CNBX Pharmaceuticals
Pharmaceutical Preparations, SIC 2834
CNBX Pharmaceuticals Inc. is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of cannabinoid-based products and technologies for cancer treatment. Its development pipeline includes Cannabics SR, an oral capsule designed to treat advanced cancer and cancer anorexia-cachexia syndrome. The company is also developing RCC-33, a synthetic cannabinoid candidate targeting colorectal cancer as a neoadjuvant therapy before cancer staging or as an adjuvant therapy following colonoscopy. CNBX focuses on drug discovery, intellectual property protection, and regulatory approval pathways, without conducting manufacturing, distribution, or commercial sales.
The company operates its research and development activities through a government-licensed laboratory facility situated in Israel. It previously established a wholly owned Israeli subsidiary, G.R.I.N Ultra Ltd, to conduct advanced research and development. CNBX maintains its corporate headquarters and principal executive offices in Bethesda, Maryland.
Summary of the business section of CNBX Pharmaceuticals's latest annual report, written by StockData.
Company profile
Company
- Legal name
- CNBX Pharmaceuticals Inc.
- Founded
- 2004
- Headquarters
- Bethesda, MD
- Address
- #3 Bethesda Metro Center, Suite 700 20814
- Phone
- (877) 424-2429
- Employees
- 53,010, Aug 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Nevada
- Fiscal year ends
- August 31
- Auditor
- Elkana Amitai. C.P.A., Mitzpe Netofa, Israel
Stock & identifiers
- Ticker
- CNBX
- Exchange
- OTC
- Shares outstanding
- 1.61B, Jun 17, 2026
- Public float
- $251.84K, Aug 31, 2025
- Filer category
- <br>Emerging growth company
- Stock splits
- 1-for-120 reverse, May 12, 2022; 2-for-1, Jul 14, 2014; 2-for-1, Jun 30, 2014; 1-for-20 reverse, Sep 30, 2010
- SEC CIK
- 1343009
- CUSIP
- 13764M209
- ISIN
- US13764M2098
- LEI
- 549300VXUG36I0WVN749
- EIN
- 20-3373669
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
No recent ownership filings by officers or directors
CNBX Pharmaceuticals's leadership is listed in its proxy statement (Form DEF 14A).
Employees
Headcount reported in annual reports
“In 2025, an estimated 152,810 cases of colon cancer and 44,850 cases of rectal cancer will be diagnosed in the US, and a total of 53,010 people will die from these cancers.”
Corporate history
Events identified from SEC filings